Paper Details

  1. Home
  2. Paper Details

Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.

Author: BatraU, GuptaS, LokeshwarN, ShirsathP

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Osimertinib, a third-generation EGFR TKI, is a promising treatment for brain metastases in non-small cell lung cancer (NSCLC) patients with EGFR mutations, offering better blood-brain barrier penetration and efficacy against the T790M mutation compared to older TKIs and radiation therapy.
Paper Details　
Original Abstract of the Article :
Metastases to central nervous system (CNS) are very common in nonsmall cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is the most affected part of CNS where blood-brain barrier (BBB) presents a challenge to currently available chemotherapeutic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4103/ijc.IJC_532_17

データ提供：米国国立医学図書館（NLM）

EGFR-TKIs: A New Frontier in CNS Metastasis Treatment

Cancer research is a vast and ever-evolving desert, where researchers continuously seek innovative solutions for treating this devastating disease. This review article focuses on the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in managing central nervous system (CNS) metastases in patients with non-small cell lung cancer (NSCLC) that harbor EGFR mutations. The authors discuss the challenges posed by the blood-brain barrier and the development of resistance to EGFR-TKIs, highlighting the emergence of third-generation EGFR-TKIs as a promising treatment option.

Third-Generation EGFR-TKIs: A Breakthrough in CNS Metastasis Treatment

The review highlights the significant advantages of third-generation EGFR-TKIs, such as osimertinib, in treating EGFR mutation-positive CNS metastases. These agents exhibit enhanced penetration of the blood-brain barrier and greater potency against EGFR mutations, including the common T790M mutation. Imagine third-generation EGFR-TKIs as resilient desert camels, able to navigate the challenging blood-brain barrier and reach their target with greater accuracy.

A New Era of EGFR-TKI Therapy for CNS Metastasis

This review underscores the potential of third-generation EGFR-TKIs as first-line agents for treating EGFR mutation-positive CNS metastases in NSCLC patients. By offering improved penetration and efficacy, these agents represent a significant advancement in the fight against this challenging form of cancer. The findings of this review provide a beacon of hope for patients struggling with CNS metastasis, offering a new pathway towards effective treatment and improved outcomes.

Dr.Camel's Conclusion

This review explores the emerging role of third-generation EGFR-TKIs as effective treatments for CNS metastasis in NSCLC patients. These agents, with their ability to overcome the blood-brain barrier and target resistant mutations, offer a promising new direction for treating this challenging form of cancer.
Date :
  1. Date Completed 2018-08-03
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

29292707

DOI: Digital Object Identifier

10.4103/ijc.IJC_532_17

Related Literature

Article Analysis
・Side Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.